Accéder au contenu
Merck

ATAD2 is associated with malignant characteristics of pancreatic cancer cells.

Oncology letters (2019-03-15)
Nairong Liu, Kohei Funasaka, Tomohiko Obayashi, Ryoji Miyahara, Yoshiki Hirooka, Hidemi Goto, Takeshi Senga
RÉSUMÉ

Pancreatic cancer is one of the most aggressive human cancers and is associated with a poor prognosis. To develop a novel strategy for pancreatic cancer treatment, it is essential to elucidate the molecular mechanisms underlying the invasion and proliferation of cancer cells. ATPase family AAA domain containing protein 2 (ATAD2) is a highly conserved protein with an AAA+ domain and a bromodomain. Accumulating studies have demonstrated that ATAD2 is associated with the progression of multiple cancers. The present study demonstrated that ATAD2 depletion suppressed cell invasion and migration. In addition, ATAD2 knockdown suppressed anchorage-independent growth of pancreatic cancer cells. Finally, ATAD2 depletion was demonstrated to sensitize pancreatic cancer cells to gemcitabine. The results of the present study indicate that ATAD2 is involved in the malignant characteristics of pancreatic cancer.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
Monoclonal Anti-ATAD2 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0182, purified immunoglobulin, buffered aqueous glycerol solution